Results from comparative animal experimental study on the effects of its candidate substance Libiguin® DIC2024 versus the active substance in Viagra®
Press release: Uppsala, August 26, 2019. Dicot AB (publ), developer of drugs targeting sexual dysfunctions, today announced that the company has conducted a comparative animal experimental study on the effects of its candidate substance Libiguin® DIC2024 versus the active substance in Viagra®, namely sildenafil, the latter which belongs to the substance group PDE-5 inhibitors used for treatment of erectile dysfunction. The compounds were administered to male rats, which were then introduced to female rats, who had been made sexually receptive by treatment with sex hormones (estrogen